Monitoring High-Value R&D Materials

This biotech company had already started its Unified Namespace (UNS) journey with a proof-of-concept project in mind, our recommended approach. As one of the most advanced companies in their industry, they wanted to use the UNS technology platform as a way to move a manual process—that of monitoring and tracking its highly valuable R&D materials data throughout the earliest stages of drug development—to a cloud-based, contextualized, and accessible asset. UNS is so new, that it is not well understood by many companies and is too risky to roll out on a larger scale. Both the customer and Continua, while equally committed to UNS architecture, feel that these projects are best approached in an agile, iterative way, with engineering adjustments made to find the best path forward.